Literature DB >> 7500025

Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells.

D Chauhan1, S M Kharbanda, A Ogata, M Urashima, D Frank, N Malik, D W Kufe, K C Anderson.   

Abstract

Oncostatin M (OSM) is a 28-kD glycoprotein recently identified as a growth factor for human multiple myeloma cells. It belongs to a family of distantly related cytokines that includes interleukin 6, ciliary neurotrophic factor, leukemia-inhibitory factor, and interleukin 11. These cytokines initiate signaling by inducing either homodimerization of gp130 or heterodimerization of gp130 with leukemia-inhibitory factor receptor beta components. Such dimerization in turn activates receptor-associated tyrosine kinases. In the present study using U266B1 human multiple myeloma cells, we show that OSM induces tyrosine phosphorylation and activation of JAK2, but not JAK1 or Tyk2, kinases. The results also demonstrate that OSM induces direct interaction of JAK2 kinase with Grb2, an SH2/SH3 domain containing adaptor protein. The SH2 domain of Grb2 is directly associated with tyrosine-phosphorylated JAK2. Furthermore, the presence of Sos in the JAK2-Grb2 complex suggests a role for Ras in OSM-transduced signaling.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7500025      PMCID: PMC2192257          DOI: 10.1084/jem.182.6.1801

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  36 in total

1.  The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling.

Authors:  E J Lowenstein; R J Daly; A G Batzer; W Li; B Margolis; R Lammers; A Ullrich; E Y Skolnik; D Bar-Sagi; J Schlessinger
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

2.  A protein tyrosine kinase in the interferon alpha/beta signaling pathway.

Authors:  L Velazquez; M Fellous; G R Stark; S Pellegrini
Journal:  Cell       Date:  1992-07-24       Impact factor: 41.582

3.  The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor.

Authors:  D P Gearing; M R Comeau; D J Friend; S D Gimpel; C J Thut; J McGourty; K K Brasher; J A King; S Gillis; B Mosley
Journal:  Science       Date:  1992-03-13       Impact factor: 47.728

4.  Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family.

Authors:  M Murakami; M Narazaki; M Hibi; H Yawata; K Yasukawa; M Hamaguchi; T Taga; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

5.  CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130.

Authors:  N Y Ip; S H Nye; T G Boulton; S Davis; T Taga; Y Li; S J Birren; K Yasukawa; T Kishimoto; D J Anderson
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

6.  C. elegans cell-signalling gene sem-5 encodes a protein with SH2 and SH3 domains.

Authors:  S G Clark; M J Stern; H R Horvitz
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

7.  JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.

Authors:  B A Witthuhn; F W Quelle; O Silvennoinen; T Yi; B Tang; O Miura; J N Ihle
Journal:  Cell       Date:  1993-07-30       Impact factor: 41.582

8.  Oncostatin M induces tyrosine phosphorylation in endothelial cells and activation of p62yes tyrosine kinase.

Authors:  G L Schieven; J C Kallestad; T J Brown; J A Ledbetter; P S Linsley
Journal:  J Immunol       Date:  1992-09-01       Impact factor: 5.422

9.  Interleukin-6 signal transducer gp130 mediates oncostatin M signaling.

Authors:  J Liu; B Modrell; A Aruffo; J S Marken; T Taga; K Yasukawa; M Murakami; T Kishimoto; M Shoyab
Journal:  J Biol Chem       Date:  1992-08-25       Impact factor: 5.157

10.  Leukemia inhibitory factor and interleukin-6 trigger the same immediate early response, including tyrosine phosphorylation, upon induction of myeloid leukemia differentiation.

Authors:  K A Lord; A Abdollahi; S M Thomas; M DeMarco; J S Brugge; B Hoffman-Liebermann; D A Liebermann
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

View more
  10 in total

1.  Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.

Authors:  Rodger E Tiedemann; Yuan Xao Zhu; Jessica Schmidt; Chang Xin Shi; Chris Sereduk; Hongwei Yin; Spyro Mousses; A Keith Stewart
Journal:  Cancer Res       Date:  2011-12-06       Impact factor: 12.701

Review 2.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

3.  Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation.

Authors:  J Frantsve; J Schwaller; D W Sternberg; J Kutok; D G Gilliland
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

Review 4.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

5.  Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways.

Authors:  T K Sengupta; E M Schmitt; L B Ivashkiv
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

6.  Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.

Authors:  Winnie F Tam; Ting-Lei Gu; Jing Chen; Benjamin H Lee; Lars Bullinger; Stefan Fröhling; Andrew Wang; Stefano Monti; Todd R Golub; D Gary Gilliland
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

Review 7.  STAT1 and pathogens, not a friendly relationship.

Authors:  Imen Najjar; Remi Fagard
Journal:  Biochimie       Date:  2010-02-13       Impact factor: 4.079

8.  LRRC8A critically regulates myofibroblast phenotypes and fibrotic remodeling following myocardial infarction.

Authors:  Xiyao Chen; Fuyang Zhang; Guangyu Hu; Xing Li; Lin Wang; Congye Li; Cong Huo; Rong Xu; Liming Hou; Ning Wang; Xiaoming Wang
Journal:  Theranostics       Date:  2022-07-27       Impact factor: 11.600

9.  Leptin-mediated differential regulation of microsomal triglyceride transfer protein in the intestine and liver affects plasma lipids.

Authors:  Jahangir Iqbal; Eduardo Mascareno; Streamson Chua; M Mahmood Hussain
Journal:  J Biol Chem       Date:  2020-02-11       Impact factor: 5.157

Review 10.  JAK2-STAT5B pathway and osteoblast differentiation.

Authors:  Pramod Darvin; Youn Hee Joung; Young Mok Yang
Journal:  JAKSTAT       Date:  2013-05-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.